Pyronaridine tetraphosphate + Artesunate for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more
General Track – Cycle 2 | DrugsHTA Council Recommendation (as of 08 April 2025)
The HTA Council positively recommends the government financing of Pyronaridine tetraphosphate + Artesunate for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more. (See below for more details)
Relevant Information
- Dosage Strength: 180 mg/ 60 mg
- Dosage Form: film-coated tablet
- Status: With Final HTA Council Recommendation
- Topic Assignment: Internal Assessment
- Policy Question: Should Pyronaridine tetraphosphate + Artesunate for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more be funded by the government?
- Secretary of Health Decision: Approved for inclusion in the Philippine National Formulary
Evidence and Relevant Documents